Skip to main content

Advertisement

Table 4 Results: Base case cost-effectiveness, PSA and exploratory analyses

From: Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

Treatment population Intervention Comparator Incremental results ICER (£/QALY)a Probability cost-effective (%)a Lowest SVR at which DCV + SOF remains cost-effective (%)a
Regimen Total cost (£) QALYs Regimen Total cost (£) QALYs Total cost (£) QALYs
Treatment naïve DCV + SOF 62,127 13.233 SOF + RBV 74,774 13.115 −12,647 0.118 DCV + SOF dominant 100 83.3
Treatment experienced 66,241 12.685 SOF + RBV 79,667 12.466 −13,426 0.219 DCV + SOF dominant 100 67.6
Interferon-ineligible/intolerant 64,436 12.926 SOF + RBV 76,740 12.761 −12,305 0.165 DCV + SOF dominant 100 75.2
No treatment 31,960 9.242 32,476 3.683 £8817 100 52.8
  1. DCV daclatasvir, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, RBV ribavirin, SOF sofosbuvir, SVR sustained virologic response
  2. aCost-effectiveness threshold: £20,000–£30,000/QALY